title: Association of pepsin with type II collagen (CII) breaks control of CII autoimmunity and triggers development of arthritis in rats.
abstract: Lewis rats develop arthritis after immunization with heterologous but not homologous rat type II collagen (CII). We have observed that if the rat CII is prepared by pepsin digestion without subsequent extensive purification, it is arthritogenic in Lewis rats. To address whether pepsin in the CII preparations contributed to the development of arthritis and whether this was associated with the induction of an immune response to CII, Lewis rats were immunized with rat CII of various degrees of purity and with various pepsin contents. After immunization with a crude preparation of CII, containing relatively large amounts of pepsin, Lewis rats developed arthritis with an incidence of 80% together with a strong anti-CII autoantibody production. Further purification of the CII on DEAE-Sepharose, which removes pepsin, eliminated the arthritogenic properties and the capacity to activate CII-specific B cells. Likewise, lathyritic CII, prepared without pepsin, induced neither a CII-specific immune response nor arthritis. If, however, pepsin was added to non-arthritogenic batches of rat CII, arthritis appeared at an incidence of 40%. By using an ELISPOT technique to detect antigen-specific interferon-gamma-producing T cells and antibody-producing B cells, the immune response to CII and pepsin can be evaluated. Eleven days after immunization with lathyritic CII and pepsin, a B-cell response towards both CII and pepsin was seen. Pepsin-specific T cells were also seen at day 11, but CII-specific T cells did not appear until day 14 after immunization. In addition, a weak CII-specific proliferative response of the T cells could be demonstrated at day 14 but not at day 11 or 12. These data show that pepsin plays an important role in the triggering of a CII-specific immune response. We suggest a carrier-hapten mechanism where pepsin acts as a carrier and CII as a 'hapten' which will activate CII-specific B cells. Subsequently these CII-specific B cells will break the T-cell tolerance and evoke a T-cell-mediated immune response towards CII.
authors.affiliation: Department of Medical and Physiological Chemistry, Uppsala University, Sweden.
authors.forename: C
authors.initials: C
authors.lastname: Vingsbo
authors.forename: P
authors.initials: P
authors.lastname: Larsson
authors.forename: M
authors.initials: M
authors.lastname: Andersson
authors.forename: R
authors.initials: R
authors.lastname: Holmdahl
mesh_terms: D000818:Animals; D000917:Antibody Formation; D001169:Arthritis, Experimental / Q000276:immunology; D001327:Autoimmune Diseases / Q000276:immunology*; D003094:Collagen / Q000276:immunology* / Q000378:metabolism; D008213:Lymphocyte Activation; D010434:Pepsin A / Q000276:immunology* / Q000378:metabolism; D051381:Rats; D011917:Rats, Inbred Lew / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D003094:Collagen; D010434:Pepsin A